Applies to Employer plans.
Covered (preferred drug)Qualification pathways
You can qualify through any one of these.
Adult obesity - BMI ≥ 30
All of:
- Member is 18 years of age or older
- Initial BMI ≥ 30 kg/m2
- Completed at least 6-month trial of comprehensive weight loss plan (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
- Member will use medication as adjunct to comprehensive weight management plan
Adult obesity - BMI ≥ 27 with comorbidity
All of:
- Member is 18 years of age or older
- Initial BMI ≥ 27 kg/m2
- At least one weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes)
- Completed at least 6-month trial of comprehensive weight loss plan (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
- Member will use medication as adjunct to comprehensive weight management plan
Documentation to bring
- Documentation that member is 18 years of age or older
- Baseline BMI documentation: BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes)
- Physician attestation or documentation of completed at least 6-month comprehensive weight loss program (reduced calorie diet, increased physical activity, behavioral modifications) prior to initiation
- Physician attestation that member will use medication as adjunct to comprehensive weight management plan
- Chart notes or lab results supporting medical necessity
- For continuation: documentation that patient is on 5 mg, 10 mg, or 15 mg dose
- For continuation: documentation of weight loss ≥ 5% of baseline body weight within first 20 weeks OR continued weight loss OR maintained plateau weight
- For continuation: documentation of adherence to and tolerance of recommended maintenance dose for at least 3 consecutive months
- For continuation: documentation of ongoing comprehensive weight management plan
Quantity limits
- all strengths — 1-month supply (28 to 30 days); 75% of days must be exhausted before refill
Approval and renewal
- Initial approval: 6 months
- Renewal: every 12 months
- Renewal: Must meet ONE of: (a) documented weight loss of at least 5% of baseline body weight after first 20 weeks of treatment; OR (b) demonstrated continued weight loss; OR (c) maintaining plateau weight achieved with diet/exercise. Patient must also be adherent and tolerating recommended maintenance dose for at least 3 consecutive months, and continue with comprehensive weight management plan.
- Renewal: Staying on a maintenance dose of at least 5 mg.
Not covered when
- Pediatric patients (under 18) not covered for Zepbound
- Mail order pharmacy benefit excluded
- Members with BCBSMA Focused Formulary: not a covered benefit effective 1/1/2026
- Requests based exclusively on use of samples will not meet coverage criteria
Policy note: Continuation requires patient is on 5 mg, 10 mg, or 15 mg dose (maintenance doses). The continuation window for weight loss assessment is 20 weeks (vs. 16 weeks for Wegovy). Policy does not specify pediatric criteria for Zepbound — age minimum is 18 per explicit policy language.
Policy effective May 1, 2026 · verified June 2, 2026 · source: 572%20 GLP-1%20and%20 GLP-1%20 %20 Gip%20 Agonist%20 Drugs%20for%20 Anti Obesity%20 Management%20and%20 Other%20 Non Obesity%20 Conditions · View policy document (PDF)